{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T17:54:26Z","timestamp":1777226066275,"version":"3.51.4"},"reference-count":150,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.4065\/mcp.2009.0535","type":"journal-article","created":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T13:28:19Z","timestamp":1270128499000},"page":"365-379","source":"Crossref","is-referenced-by-count":40,"title":["A \u201cHot\u201d Topic in Dyslipidemia Management\u2014\u201cHow to Beat a Flush\u201d: Optimizing Niacin Tolerability to Promote Long-term Treatment Adherence and Coronary Disease Prevention"],"prefix":"10.4065","volume":"85","author":[{"given":"Terry A.","family":"Jacobson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25","key":"10.4065\/mcp.2009.0535_bib1","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","author":"Adult Treatment Panel","year":"2002","journal-title":"Circulation"},{"issue":"Suppl 2","key":"10.4065\/mcp.2009.0535_bib2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/01.hjr.0000277983.23934.c9","volume":"14","author":"Graham","year":"2007","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"issue":"6","key":"10.4065\/mcp.2009.0535_bib3","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/hrt.2007.125401","article-title":"Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels","volume":"94","author":"Hausenloy","year":"2008","journal-title":"Heart"},{"issue":"2","key":"10.4065\/mcp.2009.0535_bib4","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0003-9861(55)90070-9","article-title":"Influence of nicotinic acid on serum cholesterol in man","volume":"54","author":"Altschul","year":"1955","journal-title":"Arch Biochem"},{"issue":"6","key":"10.4065\/mcp.2009.0535_bib5","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.4065\/mcp.2009.0535_bib6","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","author":"Coronary Drug Project Research Group","year":"1975","journal-title":"JAMA"},{"issue":"1","key":"10.4065\/mcp.2009.0535_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/01.CIR.88.1.20","article-title":"Beneficial effects of colestipol-niacin therapy on the common carotid artery: two- and four-year reduction of intima-media thickness measured by ultrasound","volume":"88","author":"Blankenhorn","year":"1993","journal-title":"Circulation"},{"issue":"23","key":"10.4065\/mcp.2009.0535_bib8","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1001\/jama.1987.03390230069027","article-title":"Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts","volume":"257","author":"Blankenhorn","year":"1987","journal-title":"JAMA"},{"issue":"19","key":"10.4065\/mcp.2009.0535_bib9","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"issue":"22","key":"10.4065\/mcp.2009.0535_bib10","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"issue":"10","key":"10.4065\/mcp.2009.0535_bib11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/ajhp\/60.10.995","article-title":"Niacin for dyslipidemia: considerations in product selection","volume":"60","author":"McKenney","year":"2003","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"10.4065\/mcp.2009.0535_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/0003-4819-142-2-200501180-00008","article-title":"A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events","volume":"142","author":"Whitney","year":"2005","journal-title":"Ann Intern Med"},{"issue":"22","key":"10.4065\/mcp.2009.0535_bib13","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima-media thickness","volume":"361","author":"Taylor","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"10.4065\/mcp.2009.0535_bib14","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1185\/030079906X148508","article-title":"The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3","volume":"22","author":"Taylor","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"23","key":"10.4065\/mcp.2009.0535_bib15","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"issue":"12A","key":"10.4065\/mcp.2009.0535_bib16","doi-asserted-by":"crossref","first-page":"51L","DOI":"10.1016\/S0002-9149(00)01471-5","article-title":"Evaluating niacin in its various forms","volume":"86","author":"Knopp","year":"2000","journal-title":"Am J Cardiol"},{"issue":"8A","key":"10.4065\/mcp.2009.0535_bib17","doi-asserted-by":"crossref","first-page":"20B","DOI":"10.1016\/j.amjcard.2008.02.029","article-title":"Mechanism of action of niacin","volume":"101","author":"Kamanna","year":"2008","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.4065\/mcp.2009.0535_bib18","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.bcp.2005.11.019","article-title":"Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways","volume":"71","author":"Knowles","year":"2006","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"10.4065\/mcp.2009.0535_bib19","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1001\/archinte.164.7.697","article-title":"New perspectives on the use of niacin in the treatment of lipid disorders","volume":"164","author":"McKenney","year":"2004","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.4065\/mcp.2009.0535_bib20","first-page":"1053","article-title":"Treatment of lipids: implications for the general practitioner","volume":"25","author":"Simons","year":"1996","journal-title":"Aust Fam Physician"},{"issue":"5","key":"10.4065\/mcp.2009.0535_bib21","doi-asserted-by":"crossref","first-page":"404","DOI":"10.18553\/jmcp.2004.10.5.404","article-title":"Persistence with lipid-lowering therapy: influence of the type of lipid-lowering agent and drug benefit plan option in elderly patients","volume":"10","author":"Abughosh","year":"2004","journal-title":"J Manag Care Pharm"},{"issue":"4","key":"10.4065\/mcp.2009.0535_bib22","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.288.4.462","article-title":"Adherence with statin therapy in elderly patients with and without acute coronary syndromes","volume":"288","author":"Jackevicius","year":"2002","journal-title":"JAMA"},{"issue":"4","key":"10.4065\/mcp.2009.0535_bib23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.288.4.455","article-title":"Long-term persistence in use of statin therapy in elderly patients","volume":"288","author":"Benner","year":"2002","journal-title":"JAMA"},{"issue":"18","key":"10.4065\/mcp.2009.0535_bib24","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jama.279.18.1458","article-title":"Persistence of use of lipid-lowering medications: a cross-national study","volume":"279","author":"Avorn","year":"1998","journal-title":"JAMA"},{"issue":"17","key":"10.4065\/mcp.2009.0535_bib25","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJM199504273321703","article-title":"Discontinuation of antihyperlipidemic drugs\u2013do rates reported in clinical trials reflect rates in primary care settings?","volume":"332","author":"Andrade","year":"1995","journal-title":"N Engl J Med"},{"issue":"11","key":"10.4065\/mcp.2009.0535_bib26","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.clinthera.2008.11.012","article-title":"Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel","volume":"30","author":"Chodick","year":"2008","journal-title":"Clin Ther"},{"issue":"7-8","key":"10.4065\/mcp.2009.0535_bib27","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1345\/aph.1G646","article-title":"Adherence and persistence with single-dosage form extended-release niacin\/lovastatin compared with statins alone or in combination with extended-release niacin","volume":"40","author":"LaFleur","year":"2006","journal-title":"Ann PharmacoTher"},{"issue":"1","key":"10.4065\/mcp.2009.0535_bib28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.clinthera.2009.01.011","article-title":"Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview","volume":"31","author":"Kamal-Bahl","year":"2009","journal-title":"Clin Ther"},{"issue":"6","key":"10.4065\/mcp.2009.0535_bib29","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1185\/03007990802083408","article-title":"Dosage, titration, and gaps in treatment with extended release niacin in clinical practice","volume":"24","author":"Kamal-Bahl","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"10.4065\/mcp.2009.0535_bib30","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/0026-0495(85)90092-7","article-title":"Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin","volume":"34","author":"Knopp","year":"1985","journal-title":"Metabolism"},{"issue":"12","key":"10.4065\/mcp.2009.0535_bib31","doi-asserted-by":"crossref","first-page":"996","DOI":"10.7326\/0003-4819-139-12-200312160-00009","article-title":"Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia","volume":"139","author":"Meyers","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.4065\/mcp.2009.0535_bib32","author":"Abbott"},{"key":"10.4065\/mcp.2009.0535_bib33","author":"Abbott"},{"key":"10.4065\/mcp.2009.0535_bib34","author":"Abbott"},{"issue":"12","key":"10.4065\/mcp.2009.0535_bib35","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1038\/sj.jid.5700586","article-title":"Langerhans cells release prostaglandin D2 in response to nicotinic acid","volume":"126","author":"Maciejewski-Lenoir","year":"2006","journal-title":"J Invest Dermatol"},{"issue":"12","key":"10.4065\/mcp.2009.0535_bib36","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1172\/JCI23626","article-title":"GPR109A (PUMA-G\/HM74A) mediates nicotinic acid-induced flushing","volume":"115","author":"Beny\u00f3","year":"2005","journal-title":"J Clin Invest"},{"issue":"12","key":"10.4065\/mcp.2009.0535_bib37","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1172\/JCI27160","article-title":"Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid","volume":"115","author":"Pike","year":"2005","journal-title":"J Clin Invest"},{"issue":"2","key":"10.4065\/mcp.2009.0535_bib38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0090-6980(89)90088-9","article-title":"Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid","volume":"38","author":"Morrow","year":"1989","journal-title":"Prostaglandins"},{"issue":"17","key":"10.4065\/mcp.2009.0535_bib39","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.0601574103","article-title":"Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans","volume":"103","author":"Cheng","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.4065\/mcp.2009.0535_bib40","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1124\/mol.106.030833","article-title":"Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells","volume":"70","author":"Beny\u00f3","year":"2006","journal-title":"Mol Pharmacol"},{"issue":"6","key":"10.4065\/mcp.2009.0535_bib41","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1517\/14656566.5.6.1385","article-title":"Extended-release niacin for modifying the lipoprotein profile","volume":"5","author":"Guyton","year":"2004","journal-title":"Expert Opin PharmacoTher"},{"issue":"12A","key":"10.4065\/mcp.2009.0535_bib42","doi-asserted-by":"crossref","first-page":"35L","DOI":"10.1016\/S0002-9149(00)01468-5","article-title":"The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol","volume":"86","author":"Piepho","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.4065\/mcp.2009.0535_bib43","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jacl.2007.04.003","article-title":"The role of nicotinic acid metabolites in flushing and hepatotoxicity","volume":"1","author":"Stern","year":"2007","journal-title":"J Clin Lipidol"},{"issue":"9","key":"10.4065\/mcp.2009.0535_bib44","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jama.1994.03510330050033","article-title":"A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients","volume":"271","author":"McKenney","year":"1994","journal-title":"JAMA"},{"issue":"3","key":"10.4065\/mcp.2009.0535_bib45","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0002-9343(91)90122-E","article-title":"Niacin revisited: clinical observations on an important but underutilized drug","volume":"91","author":"Henkin","year":"1991","journal-title":"Am J Med"},{"issue":"1","key":"10.4065\/mcp.2009.0535_bib46","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/clpt.1991.104","article-title":"Tolerance to nicotinic acid flushing","volume":"50","author":"Stern","year":"1991","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.4065\/mcp.2009.0535_bib47","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2796.2005.01528.x","article-title":"Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review","volume":"258","author":"Carlson","year":"2005","journal-title":"J Intern Med"},{"key":"10.4065\/mcp.2009.0535_bib48","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jacl.2009.02.003","article-title":"Flushing and other dermatologic adverse events associated with extended-release niacin therapy","volume":"3","author":"Guyton","year":"2009","journal-title":"J Clin Lipidol"},{"issue":"8A","key":"10.4065\/mcp.2009.0535_bib49","doi-asserted-by":"crossref","first-page":"14B","DOI":"10.1016\/j.amjcard.2008.02.028","article-title":"Niacin use and cutaneous flushing: mechanisms and strategies for prevention","volume":"101","author":"Davidson","year":"2008","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.4065\/mcp.2009.0535_bib50","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjcard.2004.03.042","article-title":"A meta-analysis of randomized controlled studies on the effects of extended-release niacin in women","volume":"94","author":"Goldberg","year":"2004","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.4065\/mcp.2009.0535_bib51","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00044011-200929040-00001","article-title":"Flushing ASsessment Tool (FAST): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy","volume":"29","author":"Kawata","year":"2009","journal-title":"Clin Drug Investig"},{"issue":"7","key":"10.4065\/mcp.2009.0535_bib52","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1185\/030079907X199637","article-title":"Validation of a questionnaire to assess niacin-induced cutaneous flushing","volume":"23","author":"Norquist","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"10.4065\/mcp.2009.0535_bib53","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1742-1241.2008.01739.x","article-title":"Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial","volume":"62","author":"Paolini","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.4065\/mcp.2009.0535_bib54","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacl.2009.02.009","article-title":"Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: the SUPREME study","volume":"3","author":"Insull","year":"2009","journal-title":"J Clin Lipidol"},{"key":"10.4065\/mcp.2009.0535_bib55","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jacl.2008.02.004","article-title":"Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study","volume":"2","author":"Ballantyne","year":"2008","journal-title":"J Clin Lipidol"},{"issue":"10","key":"10.4065\/mcp.2009.0535_bib56","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.amjcard.2008.02.092","article-title":"Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study)","volume":"101","author":"Ballantyne","year":"2008","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.4065\/mcp.2009.0535_bib57","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2165\/00129784-200808020-00001","article-title":"Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study","volume":"8","author":"Karas","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"issue":"16","key":"10.4065\/mcp.2009.0535_bib58","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jacc.2008.03.003","article-title":"Lipid-altering efficacy and safety of ezetimibe\/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia","volume":"51","author":"Guyton","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.4065\/mcp.2009.0535_bib59","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.atherosclerosis.2006.11.037","article-title":"Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)","volume":"192","author":"McKenney","year":"2007","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.4065\/mcp.2009.0535_bib60","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archinte.164.10.1121","article-title":"Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis","volume":"164","author":"Insull","year":"2004","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.4065\/mcp.2009.0535_bib61","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1520-037X.2004.3217.x","article-title":"Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia","volume":"7","author":"Capuzzi","year":"2004","journal-title":"Prev Cardiol"},{"issue":"11","key":"10.4065\/mcp.2009.0535_bib62","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/S0002-9149(03)00318-7","article-title":"Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels","volume":"91","author":"Capuzzi","year":"2003","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.4065\/mcp.2009.0535_bib63","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0002-9149(03)00007-9","article-title":"Comparison of once-daily, niacin extended-release\/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE])","volume":"91","author":"Bays","year":"2003","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.4065\/mcp.2009.0535_bib64","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0002-9149(01)02338-4","article-title":"Long-term safety and efficacy of a once-daily niacin\/lovastatin formulation for patients with dyslipidemia","volume":"89","author":"Kashyap","year":"2002","journal-title":"Am J Cardiol"},{"issue":"12A","key":"10.4065\/mcp.2009.0535_bib65","doi-asserted-by":"crossref","first-page":"74U","DOI":"10.1016\/S0002-9149(98)00731-0","article-title":"Efficacy and safety of an extended-release niacin (Niaspan): a long-term study","volume":"82","author":"Capuzzi","year":"1998","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.4065\/mcp.2009.0535_bib66","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1532-5415.1992.tb01822.x","article-title":"Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin","volume":"40","author":"Keenan","year":"1992","journal-title":"J Am Geriatr Soc"},{"issue":"7","key":"10.4065\/mcp.2009.0535_bib67","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/archinte.1991.00400070172024","article-title":"Niacin revisited: a randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia","volume":"151","author":"Keenan","year":"1991","journal-title":"Arch Intern Med"},{"issue":"14","key":"10.4065\/mcp.2009.0535_bib68","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/archinte.162.14.1568","article-title":"Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial","volume":"162","author":"Grundy","year":"2002","journal-title":"Arch Intern Med"},{"issue":"12A","key":"10.4065\/mcp.2009.0535_bib69","doi-asserted-by":"crossref","first-page":"35U","DOI":"10.1016\/S0002-9149(98)00952-7","article-title":"Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study","volume":"82","author":"Goldberg","year":"1998","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.4065\/mcp.2009.0535_bib70","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0026-0495(98)90284-0","article-title":"Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia","volume":"47","author":"Knopp","year":"1998","journal-title":"Metabolism"},{"issue":"suppl 12A","key":"10.4065\/mcp.2009.0535_bib71","doi-asserted-by":"crossref","first-page":"29U","DOI":"10.1016\/S0002-9149(98)00732-2","article-title":"A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients","volume":"82","author":"Morgan","year":"1998","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.4065\/mcp.2009.0535_bib72","doi-asserted-by":"crossref","first-page":"633","DOI":"10.5414\/CPP44633","article-title":"Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation","volume":"44","author":"Cefali","year":"2006","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"6","key":"10.4065\/mcp.2009.0535_bib73","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0002-9149(98)00448-2","article-title":"Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia","volume":"82","author":"Guyton","year":"1998","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.4065\/mcp.2009.0535_bib74","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","article-title":"Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials","volume":"45","author":"Birjmohun","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.4065\/mcp.2009.0535_bib75","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1067\/mhj.2002.120158","article-title":"Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy","volume":"143","author":"Wink","year":"2002","journal-title":"Am Heart J"},{"issue":"10","key":"10.4065\/mcp.2009.0535_bib76","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jama.284.10.1263","article-title":"Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial","volume":"284","author":"Elam","year":"2000","journal-title":"JAMA"},{"issue":"2","key":"10.4065\/mcp.2009.0535_bib77","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0002-9149(97)00303-2","article-title":"Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg\/dl in patients with hyperlipidemia and coronary artery disease","volume":"80","author":"Brown","year":"1997","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.4065\/mcp.2009.0535_bib78","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S0002-9149(97)00109-4","article-title":"Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia","volume":"79","author":"Mostaza","year":"1997","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.4065\/mcp.2009.0535_bib79","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0002-9149(99)80134-9","article-title":"Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia","volume":"76","author":"O'Keefe","year":"1995","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.4065\/mcp.2009.0535_bib80","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1001\/archinte.1994.00420010101012","article-title":"Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia","volume":"154","author":"Vega","year":"1994","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.4065\/mcp.2009.0535_bib81","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0002-9343(94)90298-4","article-title":"Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia","volume":"97","author":"King","year":"1994","journal-title":"Am J Med"},{"issue":"4","key":"10.4065\/mcp.2009.0535_bib82","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2125.1992.tb04067.x","article-title":"A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia","volume":"33","author":"O'Kane","year":"1992","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.4065\/mcp.2009.0535_bib83","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/jama.1990.03450060069031","article-title":"Nicotinic acid as therapy for dyslipidemia in noninsulin-dependent diabetes mellitus","volume":"264","author":"Garg","year":"1990","journal-title":"JAMA"},{"issue":"10","key":"10.4065\/mcp.2009.0535_bib84","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1001\/archfami.5.10.567","article-title":"Clinical trial of wax-matrix sustained-release niacin in a Russian population with hypercholesterolemia","volume":"5","author":"Aronov","year":"1996","journal-title":"Arch Fam Med"},{"issue":"3","key":"10.4065\/mcp.2009.0535_bib85","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0002-9149(99)80056-3","article-title":"Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia","volume":"76","author":"Vacek","year":"1995","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.4065\/mcp.2009.0535_bib86","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/0002-9149(92)90868-Y","article-title":"Marked benefit with sustained-release niacin therapy in patients with \u201cisolated\u201d very low levels of high-density lipoprotein cholesterol and coronary artery disease","volume":"69","author":"Lavie","year":"1992","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.4065\/mcp.2009.0535_bib87","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1067\/mhj.2002.123145","article-title":"A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression","volume":"144","author":"Kuvin","year":"2002","journal-title":"Am Heart J"},{"issue":"5","key":"10.4065\/mcp.2009.0535_bib88","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0002-9149(94)90005-1","article-title":"Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia","volume":"73","author":"Davignon","year":"1994","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.4065\/mcp.2009.0535_bib89","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1159\/000155896","article-title":"Prolonged-release nicotinic acid in patients with atherosclerotic disease in the Netherlands","volume":"41","author":"Poldermans","year":"2008","journal-title":"Eur Surg Res"},{"issue":"3","key":"10.4065\/mcp.2009.0535_bib90","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.amjcard.2004.04.024","article-title":"Safety and compliance with once-daily niacin extended-release\/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study","volume":"94","author":"Rubenfire","year":"2004","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.4065\/mcp.2009.0535_bib91","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1607-551X(09)70309-2","article-title":"Randomized comparative study of the effects of treatment with once-daily, niacin extended-release\/lovastatin and with simvastatin on lipid profile and fibrinolytic parameters in Taiwan","volume":"22","author":"Lin","year":"2006","journal-title":"Kaohsiung J Med Sci"},{"issue":"1","key":"10.4065\/mcp.2009.0535_bib92","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/vhrm.2006.2.1.87","article-title":"Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in Asian Indian dyslipidemic patients: a multicentric study","volume":"2","author":"Sharma","year":"2006","journal-title":"Vasc Health Risk Manag"},{"issue":"8","key":"10.4065\/mcp.2009.0535_bib93","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1177\/135965350601100802","article-title":"Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148","volume":"11","author":"Dub\u00e9","year":"2006","journal-title":"Antivir Ther"},{"issue":"9","key":"10.4065\/mcp.2009.0535_bib94","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1053\/meta.2002.34701","article-title":"Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes","volume":"51","author":"Pan","year":"2002","journal-title":"Metabolism"},{"issue":"12","key":"10.4065\/mcp.2009.0535_bib95","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1592\/phco.21.20.1473.34481","article-title":"Cholesterol and glycemic effects of Niaspan in patients with type 2 diabetes","volume":"21","author":"Kane","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.4065\/mcp.2009.0535_bib96","first-page":"215","article-title":"Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol","volume":"60","author":"Harikrishnan","year":"2008","journal-title":"Indian Heart J"},{"issue":"7","key":"10.4065\/mcp.2009.0535_bib97","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1185\/030079907X199682","article-title":"Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients","volume":"23","author":"Birjmohun","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.4065\/mcp.2009.0535_bib98","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1185\/030079906X89766","article-title":"Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study","volume":"22","author":"Vogt","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"10.4065\/mcp.2009.0535_bib99","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1001\/archinte.160.8.1177","article-title":"Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol","volume":"160","author":"Guyton","year":"2000","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.4065\/mcp.2009.0535_bib100","first-page":"326","article-title":"Efficacy and safety of one-year treatment with slow-release nicotinic acid:onitoring of drug concentration in serum","volume":"36","author":"Chojnowska-Jezierska","year":"1998","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"11","key":"10.4065\/mcp.2009.0535_bib101","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1001\/archinte.1988.00380110121025","article-title":"Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol\/high-density lipoprotein cholesterol ratio","volume":"148","author":"Luria","year":"1988","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.4065\/mcp.2009.0535_bib102","doi-asserted-by":"crossref","first-page":"252","DOI":"10.7326\/0003-4819-121-4-199408150-00003","article-title":"Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans","volume":"121","author":"Gray","year":"1994","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.4065\/mcp.2009.0535_bib103","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0025-6196(12)60824-6","article-title":"Low-dose, time-release nicotinic acid: effects in selected patients with low concentrations of high-density lipoprotein cholesterol","volume":"67","author":"Squires","year":"1992","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.4065\/mcp.2009.0535_bib104","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0002-9343(97)00311-2","article-title":"A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia","volume":"104","author":"McKenney","year":"1998","journal-title":"Am J Med"},{"issue":"12","key":"10.4065\/mcp.2009.0535_bib105","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0002-9149(89)90754-6","article-title":"Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio","volume":"64","author":"Alderman","year":"1989","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.4065\/mcp.2009.0535_bib106","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4158\/EP.12.2.159","article-title":"Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia","volume":"12","author":"Jelesoff","year":"2006","journal-title":"Endocr Pract"},{"issue":"4","key":"10.4065\/mcp.2009.0535_bib107","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0002-9343(99)80185-5","article-title":"The prevalence of side effects with regular and sustained-release nicotinic acid","volume":"99","author":"Gibbons","year":"1995","journal-title":"Am J Med"},{"key":"10.4065\/mcp.2009.0535_bib108","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1472-6904-3-4","article-title":"The safety of over-the-counter niacin: a randomized placebo-controlled trial","volume":"3","author":"Mills","year":"2003","journal-title":"BMC Clin Pharmacol"},{"issue":"10","key":"10.4065\/mcp.2009.0535_bib109","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/archinte.1996.00040041081006","article-title":"Effectiveness of low-dose crystalline nicotinic acid in men with low high-density lipoprotein cholesterol levels","volume":"156","author":"Martin-Jadraque","year":"1996","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.4065\/mcp.2009.0535_bib110","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/0272-6386(95)90133-7","article-title":"Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial","volume":"25","author":"Lal","year":"1995","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.4065\/mcp.2009.0535_bib111","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/174182679400100308","article-title":"Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients","volume":"1","author":"Tsalamandris","year":"1994","journal-title":"J Cardiovasc Risk"},{"issue":"2","key":"10.4065\/mcp.2009.0535_bib112","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0002-9149(94)90088-4","article-title":"Fluvastatin with and without niacin for hypercholesterolemia","volume":"74","author":"Jacobson","year":"1994","journal-title":"Am J Cardiol"},{"issue":"14","key":"10.4065\/mcp.2009.0535_bib113","doi-asserted-by":"crossref","first-page":"25D","DOI":"10.1016\/0002-9149(94)90629-7","article-title":"Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety","volume":"73","author":"Jacobson","year":"1994","journal-title":"Am J Cardiol"},{"issue":"10","key":"10.4065\/mcp.2009.0535_bib114","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0002-9149(93)90820-3","article-title":"Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium and lovastatin) for treating hypercholesterolemia in veterans","volume":"71","author":"Schectman","year":"1993","journal-title":"Am J Cardiol"},{"issue":"23","key":"10.4065\/mcp.2009.0535_bib115","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1001\/jama.1990.03450230043027","article-title":"Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens","volume":"264","author":"Kane","year":"1990","journal-title":"JAMA"},{"issue":"6","key":"10.4065\/mcp.2009.0535_bib116","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/j.1875-9114.1997.tb03095.x","article-title":"Experience with crystalline niacin as the preferred drug for dyslipidemia in a specialty clinic","volume":"17","author":"Rindone","year":"1997","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.4065\/mcp.2009.0535_bib117","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1177\/106002809703100602","article-title":"Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control","volume":"31","author":"Gardner","year":"1997","journal-title":"Ann PharmacoTher"},{"issue":"6","key":"10.4065\/mcp.2009.0535_bib118","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00043798-200212000-00007","article-title":"Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy","volume":"9","author":"Duvall","year":"2002","journal-title":"J Cardiovasc Risk"},{"issue":"4","key":"10.4065\/mcp.2009.0535_bib119","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0002-9149(01)02258-5","article-title":"Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events","volume":"89","author":"Taher","year":"2002","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.4065\/mcp.2009.0535_bib120","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1183\/09031936.00127507","article-title":"Health belief model predicts adherence to CPAP before experience with CPAP","volume":"32","author":"Olsen","year":"2008","journal-title":"Eur Respir J"},{"issue":"10","key":"10.4065\/mcp.2009.0535_bib121","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/j.1365-2036.2005.02497.x","article-title":"Utility of the Health Belief Model in predicting compliance of screening in patients with chronic hepatitis B","volume":"21","author":"Wai","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.4065\/mcp.2009.0535_bib122","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/109019818801500203","article-title":"Social learning theory and the Health Belief Model","volume":"15","author":"Rosenstock","year":"1988","journal-title":"Health Educ Q"},{"issue":"3","key":"10.4065\/mcp.2009.0535_bib123","first-page":"268","article-title":"Compliance with a medical regimen for asthma: a test of the health belief model","volume":"93","author":"Becker","year":"1978","journal-title":"Public Health Rep"},{"issue":"12","key":"10.4065\/mcp.2009.0535_bib124","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1517\/14656566.3.12.1763","article-title":"Niacin extended-release\/lovastatin: combination therapy for lipid disorders","volume":"3","author":"Moon","year":"2002","journal-title":"Expert Opin PharmacoTher"},{"issue":"6A","key":"10.4065\/mcp.2009.0535_bib125","doi-asserted-by":"crossref","first-page":"22C","DOI":"10.1016\/j.amjcard.2006.11.018","article-title":"Safety considerations with niacin therapy","volume":"99","author":"Guyton","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.4065\/mcp.2009.0535_bib126","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jacl.2009.02.010","article-title":"Clinical lipidology roundtable: the use of niacin","volume":"3","author":"Brown","year":"2009","journal-title":"J Clin Lipidol"},{"issue":"24","key":"10.4065\/mcp.2009.0535_bib127","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1093\/ajhp\/54.24.2815","article-title":"ASHP Therapeutic Position Statement on the safe use of niacin in the management of dyslipidemias","volume":"54","author":"American Society of Health-System Pharmacists","year":"1997","journal-title":"Am J Health Syst Pharm"},{"issue":"Suppl 3","key":"10.4065\/mcp.2009.0535_bib128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00019053-200422003-00003","article-title":"Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy","volume":"22","author":"Benner","year":"2004","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.4065\/mcp.2009.0535_bib129","doi-asserted-by":"crossref","first-page":"78","DOI":"10.5414\/CPP45078","article-title":"Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation","volume":"45","author":"Cefali","year":"2007","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"10.4065\/mcp.2009.0535_bib130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF03256578","article-title":"Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia","volume":"9","author":"Thakkar","year":"2009","journal-title":"Am J Cardiovasc Drugs"},{"issue":"10","key":"10.4065\/mcp.2009.0535_bib131","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1185\/03007990802381034","article-title":"Influence of the timing of low-dose aspirin on tolerability of prolonged-release nicotinic acid in patients at elevated cardiovascular risk","volume":"24","author":"Alves","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"10.4065\/mcp.2009.0535_bib132","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1525-1497.1997.07118.x","article-title":"Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions","volume":"12","author":"Jungnickel","year":"1997","journal-title":"J Gen Intern Med"},{"issue":"7","key":"10.4065\/mcp.2009.0535_bib133","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00045391-199506000-00006","article-title":"Low-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration","volume":"2","author":"Dunn","year":"1995","journal-title":"Am J Ther"},{"issue":"2","key":"10.4065\/mcp.2009.0535_bib134","first-page":"165","article-title":"The effect of aspirin on niacin-induced cutaneous reactions","volume":"34","author":"Whelan","year":"1992","journal-title":"J Fam Pract"},{"issue":"6","key":"10.4065\/mcp.2009.0535_bib135","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1368-5031.2006.00957.x","article-title":"Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment","volume":"60","author":"Oberwittler","year":"2006","journal-title":"Int J Clin Pract"},{"issue":"6","key":"10.4065\/mcp.2009.0535_bib136","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/sj.clpt.6100345","article-title":"Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist","volume":"83","author":"Lai","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.4065\/mcp.2009.0535_bib137","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/sj.clpt.6100180","article-title":"Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1","volume":"81","author":"Lai","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.4065\/mcp.2009.0535_bib138","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/0091270009332246","article-title":"Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms","volume":"49","author":"Dishy","year":"2009","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.4065\/mcp.2009.0535_bib139","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.amjcard.2007.10.023","article-title":"Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia","volume":"101","author":"Paolini","year":"2008","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.4065\/mcp.2009.0535_bib140","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1742-1241.2008.01938.x","article-title":"Lipid-modifying efficacy and tolerability of extended-release niacin\/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia","volume":"62","author":"Maccubbin","year":"2008","journal-title":"Int J Clin Pract"},{"issue":"4","key":"10.4065\/mcp.2009.0535_bib141","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccl.2008.06.007","article-title":"Extended-release niacin\/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors","volume":"26","author":"Paolini","year":"2008","journal-title":"Cardiol Clin"},{"issue":"1","key":"10.4065\/mcp.2009.0535_bib142","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.amjcard.2009.02.047","article-title":"Flushing profile of extended-release niacin\/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease","volume":"104","author":"Maccubbin","year":"2009","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.4065\/mcp.2009.0535_bib143","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/clpt.1989.200","article-title":"Pharmacokinetics of nicotinic acid-salicylic acid interaction","volume":"46","author":"Ding","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"10.4065\/mcp.2009.0535_bib144","series-title":"CHMP Assessment Report for Tredaptive: European Medicines Agency, Evaluation of Medicines for Human Use","author":"EMEA","year":"2008"},{"issue":"3","key":"10.4065\/mcp.2009.0535_bib145","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1177\/039463200802100304","article-title":"A quercetin containing supplement reduces niacin-induced flush in humans","volume":"21","author":"Kalogeromitros","year":"2008","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"7","key":"10.4065\/mcp.2009.0535_bib146","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/sj.bjp.0707668","article-title":"The flavonoid luteolin inhibits niacin-induced flush","volume":"153","author":"Papaliodis","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.4065\/mcp.2009.0535_bib147","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1021\/jm900151e","article-title":"Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats","volume":"52","author":"Shen","year":"2009","journal-title":"J Med Chem"},{"issue":"4","key":"10.4065\/mcp.2009.0535_bib148","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.0006-341X.2003.00109.x","article-title":"Discrete proportional hazards models for mismeasured outcomes","volume":"59","author":"Meier","year":"2003","journal-title":"Biometrics"},{"key":"10.4065\/mcp.2009.0535_bib149","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.2517-6161.1976.tb01597.x","article-title":"The empirical distribution function with arbitrarily grouped, censored, and truncated data","volume":"38","author":"Turnbull","year":"1976","journal-title":"J R Stat Soc B"},{"key":"10.4065\/mcp.2009.0535_bib150","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0731-7085(99)00177-6","article-title":"A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography","volume":"21","author":"Sagar","year":"1999","journal-title":"J Pharm Biomed Anal"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611604291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611604291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T20:29:49Z","timestamp":1739996989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611604291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":150,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0025619611604291"],"URL":"https:\/\/doi.org\/10.4065\/mcp.2009.0535","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}